These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1111 related articles for article (PubMed ID: 33189562)

  • 1. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
    Mayer EL; Ren Y; Wagle N; Mahtani R; Ma C; DeMichele A; Cristofanilli M; Meisel J; Miller KD; Abdou Y; Riley EC; Qamar R; Sharma P; Reid S; Sinclair N; Faggen M; Block CC; Ko N; Partridge AH; Chen WY; DeMeo M; Attaya V; Okpoebo A; Alberti J; Liu Y; Gauthier E; Burstein HJ; Regan MM; Tolaney SM
    J Clin Oncol; 2024 Jun; 42(17):2050-2060. PubMed ID: 38513188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials.
    Li H; Wu Y; Zou H; Koner S; Plichta JK; Tolaney SM; Zhang J; He YW; Wei Q; Tang L; Zhang H; Zhang B; Guo Y; Chen X; Li K; Lian L; Ma F; Luo S
    EBioMedicine; 2024 Jul; 105():105186. PubMed ID: 38861871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
    Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
    BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
    Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
    Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disparities in receipt of 1-
    Pilehvari A; Kimmick G; You W; Bonilla G; Anderson R
    Breast Cancer Res; 2024 Oct; 26(1):144. PubMed ID: 39425174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population.
    Chen BF; Tsai YF; Chao TC; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Liu CY; Lai JI; Tseng LM; Huang CC
    Clin Exp Med; 2024 Aug; 24(1):185. PubMed ID: 39133334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
    Sammons S; Shastry M; Dent S; Anders C; Hamilton E
    Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2- advanced breast cancer: a real-world evidence cohort.
    Sánchez-Bayona R; Lopez de Sa A; Jerez Gilarranz Y; Sanchez de Torre A; Alva M; Echavarria I; Moreno F; Tolosa P; Herrero Lopez B; de Luna A; Lema L; Gamez Casado S; Madariaga A; López-Tarruella S; Manso L; Bueno-Muiño C; Garcia-Saenz JA; Ciruelos E; Martin M
    Breast Cancer Res Treat; 2024 Aug; 206(3):551-559. PubMed ID: 38703285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
    Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting.
    Kimmick G; Pilehvari A; You W; Bonilla G; Anderson R
    Breast Cancer Res Treat; 2024 Nov; 208(2):263-273. PubMed ID: 38922546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.
    Pla H; Felip E; Obadia V; Pernas S; Viñas G; Margelí M; Fort-Culillas R; Del Barco S; Sabaté N; Fort E; Lezcano C; Cirauqui B; Quiroga V; Stradella A; Gil Gil M; Esteve A; Recalde S
    Clin Transl Oncol; 2024 Jul; 26(7):1748-1758. PubMed ID: 38519708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
    Schettini F; Palleschi M; Mannozzi F; Brasó-Maristany F; Cecconetto L; Galván P; Mariotti M; Ferrari A; Scarpi E; Miserocchi A; Nanni O; Sanfeliu E; Prat A; Rocca A; De Giorgi U
    Oncologist; 2024 May; 29(5):e622-e634. PubMed ID: 38175669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
    Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
    Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.